Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

Elizabeth L. Cooney, M. Juliana Mcelrath, Lawrence Corey, Shiu Lok Hu, Ann C. Collier, Douglas Arditti, Mark Hoffman, Robert W. Coombs, Gale E. Smith, Philip D. Greenberg

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination HIV-1 vaccine regimen (strain IIIB) consisting of priming with a recombinant vaccinia (vac/env) virus expressing HIV-1 envelope and boosting with a gp160 glycoprotein derived from a recombinant baculovirus (rgp160). T-cell and antibody responses detected after immunization with either vac/env alone or rgp160 alone were generally of low magnitude and transient, and no subject developed neutralizing antibodies. In contrast, recipients of the combination regimen demonstrated in vitro T-cell proliferative responses to homologous HIV-1 antigens that were 3- to 10-fold higher than responses with either vaccine alone, and these responses were sustained for >18 months in 75% of recipients. Moreover, both CD8+ and CD4+ cytolytic T cells were detected. Antibody responses (titer, 1:800 to 1:102,400) to homologous HIV envelope developed in all recipients of the combination regimen, and neutralizing antibodies were detected in 7 of 13. Thus, immunization with a live virus vaccine followed by boosting with a soluble protein offers promise for inducing the broad immunity needed in an HIV vaccine.

Original languageEnglish (US)
Pages (from-to)1882-1886
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume90
Issue number5
StatePublished - Mar 1 1993
Externally publishedYes

Fingerprint

Combined Vaccines
Vaccinia
HIV-1
Immunity
Vaccines
HIV
Neutralizing Antibodies
T-Lymphocytes
Viruses
Proteins
Antibody Formation
Immunization
Baculoviridae
Glycoproteins
Antigens

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. / Cooney, Elizabeth L.; Mcelrath, M. Juliana; Corey, Lawrence; Hu, Shiu Lok; Collier, Ann C.; Arditti, Douglas; Hoffman, Mark; Coombs, Robert W.; Smith, Gale E.; Greenberg, Philip D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, No. 5, 01.03.1993, p. 1882-1886.

Research output: Contribution to journalArticle

Cooney, Elizabeth L. ; Mcelrath, M. Juliana ; Corey, Lawrence ; Hu, Shiu Lok ; Collier, Ann C. ; Arditti, Douglas ; Hoffman, Mark ; Coombs, Robert W. ; Smith, Gale E. ; Greenberg, Philip D. / Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. In: Proceedings of the National Academy of Sciences of the United States of America. 1993 ; Vol. 90, No. 5. pp. 1882-1886.
@article{f06dbe5b693c440293a71b4af4e51038,
title = "Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein",
abstract = "Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination HIV-1 vaccine regimen (strain IIIB) consisting of priming with a recombinant vaccinia (vac/env) virus expressing HIV-1 envelope and boosting with a gp160 glycoprotein derived from a recombinant baculovirus (rgp160). T-cell and antibody responses detected after immunization with either vac/env alone or rgp160 alone were generally of low magnitude and transient, and no subject developed neutralizing antibodies. In contrast, recipients of the combination regimen demonstrated in vitro T-cell proliferative responses to homologous HIV-1 antigens that were 3- to 10-fold higher than responses with either vaccine alone, and these responses were sustained for >18 months in 75{\%} of recipients. Moreover, both CD8+ and CD4+ cytolytic T cells were detected. Antibody responses (titer, 1:800 to 1:102,400) to homologous HIV envelope developed in all recipients of the combination regimen, and neutralizing antibodies were detected in 7 of 13. Thus, immunization with a live virus vaccine followed by boosting with a soluble protein offers promise for inducing the broad immunity needed in an HIV vaccine.",
author = "Cooney, {Elizabeth L.} and Mcelrath, {M. Juliana} and Lawrence Corey and Hu, {Shiu Lok} and Collier, {Ann C.} and Douglas Arditti and Mark Hoffman and Coombs, {Robert W.} and Smith, {Gale E.} and Greenberg, {Philip D.}",
year = "1993",
month = "3",
day = "1",
language = "English (US)",
volume = "90",
pages = "1882--1886",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

AU - Cooney, Elizabeth L.

AU - Mcelrath, M. Juliana

AU - Corey, Lawrence

AU - Hu, Shiu Lok

AU - Collier, Ann C.

AU - Arditti, Douglas

AU - Hoffman, Mark

AU - Coombs, Robert W.

AU - Smith, Gale E.

AU - Greenberg, Philip D.

PY - 1993/3/1

Y1 - 1993/3/1

N2 - Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination HIV-1 vaccine regimen (strain IIIB) consisting of priming with a recombinant vaccinia (vac/env) virus expressing HIV-1 envelope and boosting with a gp160 glycoprotein derived from a recombinant baculovirus (rgp160). T-cell and antibody responses detected after immunization with either vac/env alone or rgp160 alone were generally of low magnitude and transient, and no subject developed neutralizing antibodies. In contrast, recipients of the combination regimen demonstrated in vitro T-cell proliferative responses to homologous HIV-1 antigens that were 3- to 10-fold higher than responses with either vaccine alone, and these responses were sustained for >18 months in 75% of recipients. Moreover, both CD8+ and CD4+ cytolytic T cells were detected. Antibody responses (titer, 1:800 to 1:102,400) to homologous HIV envelope developed in all recipients of the combination regimen, and neutralizing antibodies were detected in 7 of 13. Thus, immunization with a live virus vaccine followed by boosting with a soluble protein offers promise for inducing the broad immunity needed in an HIV vaccine.

AB - Transmission studies have suggested that an optimal human immunodeficiency virus type 1 (HIV-1) vaccine should induce both neutralizing antibodies and cytolytic T cells to eliminate free virus and infected cells. A phase I trial in healthy HIV-1-seronegative persons was conducted with a combination HIV-1 vaccine regimen (strain IIIB) consisting of priming with a recombinant vaccinia (vac/env) virus expressing HIV-1 envelope and boosting with a gp160 glycoprotein derived from a recombinant baculovirus (rgp160). T-cell and antibody responses detected after immunization with either vac/env alone or rgp160 alone were generally of low magnitude and transient, and no subject developed neutralizing antibodies. In contrast, recipients of the combination regimen demonstrated in vitro T-cell proliferative responses to homologous HIV-1 antigens that were 3- to 10-fold higher than responses with either vaccine alone, and these responses were sustained for >18 months in 75% of recipients. Moreover, both CD8+ and CD4+ cytolytic T cells were detected. Antibody responses (titer, 1:800 to 1:102,400) to homologous HIV envelope developed in all recipients of the combination regimen, and neutralizing antibodies were detected in 7 of 13. Thus, immunization with a live virus vaccine followed by boosting with a soluble protein offers promise for inducing the broad immunity needed in an HIV vaccine.

UR - http://www.scopus.com/inward/record.url?scp=0027462887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462887&partnerID=8YFLogxK

M3 - Article

C2 - 8446603

AN - SCOPUS:0027462887

VL - 90

SP - 1882

EP - 1886

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -